FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1286-1288 September 22, 2005 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lieberman, J. A. PubMed Citation

Since the discovery of the effects of chlorpromazine in the 1950s, treatment of schizophrenia has relied on antipsychotic drugs that target dopamine D2 receptors. The effectiveness of these agents in reducing the intensity of patients' delusions and hallucinations permitted outpatient treatment instead of lifelong institutionalization in state mental hospitals. The many antipsychotic drugs introduced during the next decade were increasingly potent, as medicinal chemists improved the drugs' affinity for the D2 receptor. However, the efficacy of the drugs was similar, since all had the same mechanism of action.¹ A troubling problem was that the blockade of dopaminergic neurotransmission in the . . . [Full Text of this Article]

Source Information

From the Department of Psychiatry, University of Colorado Health Sciences Center, and the Veterans Affairs Medical Center — both in Denver.

This article has been cited by other articles:

• Moscarelli, M. (2009). Passive and Active Schizophrenia: Toward a New Descriptive Micropsychopathology. Schizophr Bull 35: 1183-1196 [Abstract] [Full Text]  
• Domino, M. E., Swartz, M. S. (2008). Who Are the New Users of Antipsychotic Medications?. Psychiatr. Serv. 59: 507-514 [Abstract] [Full Text]  
• Rosenheck, R. A., Leslie, D. L., Doshi, J. A. (2008). Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making. Psychiatr. Serv. 59: 515-520 [Abstract] [Full Text]  
• Archie, S. M., Goldberg, J. O., Akhtar-Danesh, N., Landeen, J., McColl, L., McNiven, J. (2007). Psychotic Disorders, Eating Habits, and Physical Activity: Who Is Ready for Lifestyle Changes?. Psychiatr. Serv. 58: 233-239 [Abstract] [Full Text]  
• Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Sevy, S. M., Gunduz-Bruce, H., Soto-Perello, J. M., Mendelowitz, A., Khadivi, A., Miller, R., McCormack, J., Lorell, B. S., Lesser, M. L., Schooler, N. R., Kane, J. M. (2006). Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes. Am. J. Psychiatry 163: 2096-2102 [Abstract] [Full Text]  
• Insel, T. R. (2006). Beyond Efficacy: The STAR{star}D Trial. Focus 4: 562- [Full Text]  
• Huskamp, H. A. (2006). Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.. Health Aff (Millwood) 25: 635-646 [Abstract] [Full Text]  
• BASIL, B., MATHEWS, M., ADETUNJI, B., BUDUR, K. (2006). . Am. J. Psychiatry 163: 555-555 [Full Text]  
• Dettling, M., Anghelescu, I.-G., Essock, S. M., Covell, N. H., Jackson, C. T., Gupta, N., Basu, D., Duan, N., Kraemer, H. C., Mintz, J., Lieberman, J. A., Stroup, T. S., Davis, S. M., the CATIE Investigator Group, (2006). Antipsychotic Drugs and Schizophrenia. NEJM 354: 298-300 [Full Text]